L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey

scientific article

L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/ENE.13466
P698PubMed publication ID28940893

P50authorSantiago Perez-LloretQ67389929
Arnaud DelvalQ41111578
Wassilios G. MeissnerQ41111597
F TisonQ64856344
P2093author name stringA Destée
O Rascol
P Derkinderen
L Negre-Pages
of the COPARK Study Group
P Damier
P2860cites workWorsening of levodopa-induced dyskinesias by motor and mental tasksQ28372142
Exenatide and the treatment of patients with Parkinson's diseaseQ30540208
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literatureQ34273182
Levodopa and the progression of Parkinson's diseaseQ34553278
Levodopa-induced dyskinesiasQ34618170
Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson's Disease via Autophagy and Mitochondrial ROS ClearanceQ37299382
SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measuresQ37381351
Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendationsQ37716740
Classifying risk factors for dyskinesia in Parkinson's diseaseQ37769643
Health-related quality-of-life scales in Parkinson's disease: critique and recommendationsQ37898591
Wearing-off scales in Parkinson's disease: critique and recommendationsQ37903795
Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.Q40368066
Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of lifeQ40748733
Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's diseaseQ40860918
Falls in ambulatory non-demented patients with Parkinson's diseaseQ41111540
Subjective sleep dysfunction and insomnia symptoms in Parkinson's disease: Insights from a cross-sectional evaluation of the French CoPark cohortQ41303725
Health-related quality of life and its determinants in Parkinson's disease: results of an Italian cohort studyQ43975400
Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuationsQ44742022
Impact of the motor complications of Parkinson's disease on the quality of lifeQ45071670
Quality of life in relation to mood, coping strategies, and dyskinesia in Parkinson's diseaseQ45352049
Clinical determinants of health-related quality of life in Mexican patients with Parkinson's diseaseQ45697484
Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort study.Q46025359
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.Q46834396
Social and clinical determinants of quality of life in Parkinson's disease in a Russian cohort studyQ46875779
Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countriesQ48072642
Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson diseaseQ48076091
Quality of life in Parkinson's disease: the relative importance of the symptomsQ48432774
The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesiaQ50249073
Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesiaQ50263113
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.Q51247357
Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson's disease: preliminary analysis from the French COPARK cohort.Q51483415
Factors affecting the quality of life of patients with idiopathic Parkinson's disease--a cross-sectional study in an outpatient clinic attendees.Q51926119
Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.Q53509756
PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures.Q53575895
Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study.Q53708979
P433issue12
P921main subjectdyskinesiaQ629444
quality of lifeQ13100823
P304page(s)1532-1538
P577publication date2017-09-20
P1433published inEuropean Journal of NeurologyQ15757256
P1476titleL-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey
P478volume24

Reverse relations

cites work (P2860)
Q52562719Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease.
Q50079431Dyskinesias and levodopa therapy: why wait?
Q64968139Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia
Q64096099Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease
Q98290524Parkinsonian Symptoms, Not Dyskinesia, Negatively Affect Active Life Participation of Dyskinetic Patients with Parkinson's Disease
Q64901815Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.

Search more.